The greatest danger of building outside the SF bubble is not a lack of capital, but the absence of a peer group that normalizes struggle. Without that support, founders are more susceptible to the surrounding skeptical culture and more likely to give up during inevitable downturns.

Despite high costs, San Francisco's dense network of builders provides access to crucial, unwritten knowledge ('whispered secrets') that accelerates ambitious startups. Moving to SF also acts as a powerful selection filter for founder commitment, creating a unique, high-focus environment that is difficult to replicate.

While lacking investor density, cities like Houston thrive by tapping into world-class academic medical centers (e.g., MD Anderson) for talent and collaborations. Furthermore, significant state-level funding, like Texas's CPRIT, can bridge the early-stage capital gap often filled by local VCs in major hubs.

For founders in emerging markets like Africa, the most valuable asset from a community is not capital but access to good product judgment, taste, and peers. This cultivates the ability to create globally meaningful products where established tech ecosystems don't exist.

A VC advises Korean entrepreneurs to abandon gradual US entry strategies. The effective model is to "parachute" in—relocating solo to a hub like Boston and immersing oneself in the network. This radical, face-time-centric approach is deemed essential for building the momentum needed for US investment and partnerships.

Iterion CEO Rahul Aras argues that being outside a major biotech hub is a real fundraising hurdle. The issue isn't overt investor bias, but rather the loss of natural networking opportunities—like bumping into investors at a local coffee shop—that are common in dense ecosystems and must be overcome with proactive outreach.

Founded in Minnesota, Cellcuity taps the University of Minnesota and the region's medical device industry for scientific talent. For specialized roles like clinical development, it embraces a distributed team, demonstrating a viable model for building a biopharma company outside of traditional hubs.

According to Y Combinator partners, the network effects and density of talent, capital, and customers in San Francisco are so powerful that being physically based there can double a startup's chances of reaching a billion-dollar valuation compared to other major tech hubs like New York.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.